Company intelligence / Profile preview

Gossamer Bio

San Diego, California, United Statesorpha.net ↗

Ownership: Public · GOSS
Employees: ~163
Development stage: Phase 2

Overview

Gossamer Bio is currently conducting the PROSERA Study, a global registrational Phase 3 clinical trial of seralutinib in patients with WHO Functional Class II and III PAH. The primary endpoint is change in six-minute walk distance (6MWD) from baseline at week 24. Topline results are expected in the fourth quarter of 2025. The company previously reported positive results from its Phase 2 TORREY Study in PAH patients[6][8].

Therapeutic areas: PulmonologyCardiovascular
Modalities: Small molecules (inhaled PDGFR, CSF1R and c-KIT inhibitor)
Industry: Biotech

Drug pipeline

11 assets

seralutinib

10 more assets in the full pipeline.

Request access →

Partnerships

Chiesi Group[9]

Financials

Market cap: $78.1M
Total revenue: $9.2M
Enterprise value: $60.1M

Beyond the preview

Go deeper on Gossamer Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gossamer Bio.

Explore the full profile